01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
The IRS Office of Chief Counsel recently issued a Memorandum of Generic Legal Advice that makes clea...
Read More >
Retailers faced a difficult financing market before COVID-19 appeared, but lockdowns have made the s...
Read More >
Under California’s Proposition 60, which became enacted in 1986 as Revenue and Taxation Code sectio...
Read More >
The Setting Every Community Up for Retirement Enhancement Act of 2019 (the “SECURE Act”), the larg...
Read More >
On August 14, 2020, the U.S. Department of Justice (DOJ) issued its first Opinion Procedure Release ...
Read More >
The NLRB issued a number of recent decisions helpful for employers – both non-union and unionized –...
Read More >